Infinity Pharmaceuticals
Market Cap
US$55.7m
Last Updated
2020/05/25 09:39 UTC
Data Sources
Company Financials +
Executive Summary
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has Infinity Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: INFI's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-3.0%
INFI
0.7%
US Biotechs
1.8%
US Market
1 Year Return
-32.2%
INFI
22.1%
US Biotechs
3.7%
US Market
Return vs Industry: INFI underperformed the US Biotechs industry which returned 22.1% over the past year.
Return vs Market: INFI underperformed the US Market which returned 3.7% over the past year.
Shareholder returns
| INFI | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.0% | 0.7% | 1.8% |
| 30 Day | -8.5% | 4.9% | 5.6% |
| 90 Day | -24.8% | 10.7% | -7.4% |
| 1 Year | -32.2%-32.2% | 23.3%22.1% | 6.1%3.7% |
| 3 Year | -43.6%-43.6% | 36.3%31.7% | 28.3%19.8% |
| 5 Year | -92.1%-92.1% | -2.5%-8.3% | 52.4%35.1% |
Price Volatility Vs. Market
How volatile is Infinity Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
What Kind Of Shareholders Own Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)?1 month ago | Simply Wall St
Investors Who Bought Infinity Pharmaceuticals (NASDAQ:INFI) Shares Five Years Ago Are Now Down 93%2 months ago | Simply Wall St
US$2.31: That's What Analysts Think Infinity Pharmaceuticals, Inc. Is Worth After Its Latest ResultsValuation
Is Infinity Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: INFI ($0.97) is trading below our estimate of fair value ($10.15)
Significantly Below Fair Value: INFI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: INFI is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: INFI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INFI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INFI has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.
Next Steps
Future Growth
How is Infinity Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
36.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INFI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: INFI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: INFI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: INFI's revenue (73.6% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: INFI's revenue (73.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if INFI's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Infinity Pharmaceuticals performed over the past 5 years?
24.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INFI is currently unprofitable.
Growing Profit Margin: INFI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: INFI is unprofitable, but has reduced losses over the past 5 years at a rate of 24.3% per year.
Accelerating Growth: Unable to compare INFI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INFI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: INFI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Next Steps
Financial Health
How is Infinity Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: INFI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: INFI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: INFI is debt free.
Reducing Debt: INFI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INFI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: INFI has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 1.1% each year.
Next Steps
Dividend
What is Infinity Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INFI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INFI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INFI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INFI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INFI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.3yrs
Average management tenure
CEO
Adelene Perkins (59yo)
10.33yrs
Tenure
US$1,680,857
Compensation
Ms. Adelene Q. Perkins has been the Chief Executive Officer of Infinity Pharmaceuticals, Inc. since January 2, 2010 and has been its Chairman since November 2012. Ms. Perkins served as the President of Inf ...
CEO Compensation Analysis
Compensation vs Market: Adelene's total compensation ($USD1.68M) is above average for companies of similar size in the US market ($USD595.62K).
Compensation vs Earnings: Adelene's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 10.33yrs | US$1.68m | 1.41% $785.3k | |
| President & Treasurer | 3.33yrs | US$1.16m | 1.32% $735.5k | |
| Chairman of Scientific Advisory Board | 0.17yr | US$759.67k | 0.15% $85.5k | |
| Vice President of Finance | 3.33yrs | no data | no data | |
| Head of Pharmaceutical Development | 0.33yr | no data | no data | |
| Senior VP | 3.83yrs | US$1.13m | 0.20% $109.9k | |
| Senior Executive Coordinator | no data | no data | no data |
3.3yrs
Average Tenure
52.5yo
Average Age
Experienced Management: INFI's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 10.33yrs | US$1.68m | 1.41% $785.3k | |
| Chairman of Scientific Advisory Board | 0.17yr | US$759.67k | 0.15% $85.5k | |
| Independent Director | 13.67yrs | US$108.91k | 0.25% $138.8k | |
| Independent Director | 17yrs | US$96.41k | 0.087% $48.5k | |
| Lead Independent Director | no data | US$146.21k | 0.017% $9.7k | |
| Independent Director | 2.08yrs | US$86.41k | 0.010% $5.5k | |
| Independent Director | 3.08yrs | US$93.91k | no data | |
| Member of Scientific Advisory Board | 2.17yrs | no data | no data | |
| Independent Director | 6.17yrs | US$96.41k | 0.15% $82.7k | |
| Member of Scientific Advisory Board | 2.17yrs | no data | no data |
3.1yrs
Average Tenure
62yo
Average Age
Experienced Board: INFI's board of directors are considered experienced (3.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Infinity Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Infinity Pharmaceuticals, Inc.
- Ticker: INFI
- Exchange: NasdaqGS
- Founded:
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$55.705m
- Shares outstanding: 57.43m
- Website: https://www.infi.com
Number of Employees
Location
- Infinity Pharmaceuticals, Inc.
- 1100 Massachusetts Avenue
- Floor 4
- Cambridge
- Massachusetts
- 2138
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| INFI | NasdaqGS (Nasdaq Global Select) | Yes | Common Shares | US | USD | Sep 2006 |
| I3F | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Sep 2006 |
Biography
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/05/25 09:39 |
| End of Day Share Price | 2020/05/22 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.